HU230416B1 - 6-Helyzetben szubsztituált indolinonok, előállításuk és alkalmazásuk gyógyszerként - Google Patents

6-Helyzetben szubsztituált indolinonok, előállításuk és alkalmazásuk gyógyszerként Download PDF

Info

Publication number
HU230416B1
HU230416B1 HU0204587A HUP0204587A HU230416B1 HU 230416 B1 HU230416 B1 HU 230416B1 HU 0204587 A HU0204587 A HU 0204587A HU P0204587 A HUP0204587 A HU P0204587A HU 230416 B1 HU230416 B1 HU 230416B1
Authority
HU
Hungary
Prior art keywords
methyl
aniline
ethyl
amino
alkyl
Prior art date
Application number
HU0204587A
Other languages
English (en)
Hungarian (hu)
Inventor
Armin Heckel
Gerald Jürgen ROTH
Rainer Walter
Jacobus Van Meel
Norbert Redemann
Ulrike Tontsch-Grunt
Walter Spevak
Frank Hilberg
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU230416(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19949208A external-priority patent/DE19949208A1/de
Priority claimed from DE2000142696 external-priority patent/DE10042696A1/de
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of HUP0204587A2 publication Critical patent/HUP0204587A2/hu
Publication of HUP0204587A3 publication Critical patent/HUP0204587A3/hu
Priority to HUS1600022C priority Critical patent/HUS1600022I1/hu
Publication of HU230416B1 publication Critical patent/HU230416B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HU0204587A 1999-10-13 2000-10-09 6-Helyzetben szubsztituált indolinonok, előállításuk és alkalmazásuk gyógyszerként HU230416B1 (hu)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HUS1600022C HUS1600022I1 (hu) 1999-10-13 2016-05-13 6-Helyzetben szubsztituált indolinonok, elõállításuk és alkalmazásuk gyógyszerként

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19949208.5 1999-10-13
DE19949208A DE19949208A1 (de) 1999-10-13 1999-10-13 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10042696.4 2000-08-31
DE2000142696 DE10042696A1 (de) 2000-08-31 2000-08-31 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2000/009867 WO2001027081A1 (de) 1999-10-13 2000-10-09 In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
HUP0204587A2 HUP0204587A2 (en) 2003-05-28
HUP0204587A3 HUP0204587A3 (en) 2004-07-28
HU230416B1 true HU230416B1 (hu) 2016-05-30

Family

ID=26006858

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0204587A HU230416B1 (hu) 1999-10-13 2000-10-09 6-Helyzetben szubsztituált indolinonok, előállításuk és alkalmazásuk gyógyszerként
HUS1600022C HUS1600022I1 (hu) 1999-10-13 2016-05-13 6-Helyzetben szubsztituált indolinonok, elõállításuk és alkalmazásuk gyógyszerként

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1600022C HUS1600022I1 (hu) 1999-10-13 2016-05-13 6-Helyzetben szubsztituált indolinonok, elõállításuk és alkalmazásuk gyógyszerként

Country Status (43)

Country Link
EP (2) EP2157081A1 (forum.php)
JP (2) JP4021664B2 (forum.php)
KR (2) KR100835546B1 (forum.php)
CN (1) CN100455568C (forum.php)
AR (1) AR026036A1 (forum.php)
AT (1) ATE439342T1 (forum.php)
AU (1) AU781939B2 (forum.php)
BE (1) BE2015C018I2 (forum.php)
BG (1) BG65983B1 (forum.php)
BR (1) BRPI0014735B8 (forum.php)
CA (1) CA2387013C (forum.php)
CO (1) CO5261488A1 (forum.php)
CY (2) CY1110067T1 (forum.php)
CZ (1) CZ301073B6 (forum.php)
DE (1) DE50015711D1 (forum.php)
DK (1) DK1224170T5 (forum.php)
EA (1) EA006080B1 (forum.php)
EE (1) EE05427B1 (forum.php)
EG (1) EG25931A (forum.php)
ES (1) ES2331459T3 (forum.php)
FR (1) FR15C0024I2 (forum.php)
HK (1) HK1052505B (forum.php)
HR (1) HRP20020306B1 (forum.php)
HU (2) HU230416B1 (forum.php)
IL (2) IL148756A0 (forum.php)
LT (1) LTC1224170I2 (forum.php)
LU (1) LU92681I2 (forum.php)
ME (1) MEP45408A (forum.php)
MX (1) MXPA02002799A (forum.php)
MY (1) MY127956A (forum.php)
NL (1) NL300725I2 (forum.php)
NO (3) NO322746B1 (forum.php)
NZ (1) NZ518489A (forum.php)
PE (1) PE20010671A1 (forum.php)
PL (1) PL207445B1 (forum.php)
PT (1) PT1224170E (forum.php)
RS (1) RS51013B (forum.php)
SA (1) SA01210704B1 (forum.php)
SI (1) SI1224170T1 (forum.php)
SK (1) SK287312B6 (forum.php)
TW (1) TWI268922B (forum.php)
UA (1) UA75054C2 (forum.php)
WO (1) WO2001027081A1 (forum.php)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
CN101029022B (zh) 2000-10-20 2011-01-12 卫材R&D管理有限公司 含氮芳环衍生物的制备方法
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PT1401416E (pt) 2001-06-29 2007-02-28 Ab Science Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
CA2452169A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
CA2452371A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
ATE376182T1 (de) 2001-06-29 2007-11-15 Ab Science C-kit inhibitoren
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
EP1430048A1 (en) * 2001-09-27 2004-06-23 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
RU2316554C2 (ru) 2001-12-27 2008-02-10 Тереванс, Инк. Производные индолина, используемые как ингибиторы протеинкиназы
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
ITBO20020198A1 (it) * 2002-04-12 2003-10-13 Univ Bologna Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
DE602005013990D1 (de) 2004-09-17 2009-05-28 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
WO2008152013A1 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
ES2435454T3 (es) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-onas y aza-indolin-2-onas
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
PE20091445A1 (es) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int Derivados de indolinona y procedimiento para su fabricacion
NZ585799A (en) 2007-12-03 2012-04-27 Boehringer Ingelheim Int Process for the manufacture of an indolinone derivative in particular 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
HUE037291T2 (hu) 2008-06-06 2018-08-28 Boehringer Ingelheim Int Gyógyászati kombináció
TW201011002A (en) * 2008-07-29 2010-03-16 Boehringer Ingelheim Int New compounds
EP2387401A1 (en) 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
JP2012526766A (ja) 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍性及び線維性疾患の処置における新規な併用療法
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
AU2013211888B2 (en) 2012-01-26 2017-08-31 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
JP6207625B2 (ja) * 2012-12-06 2017-10-04 山東亨利醫藥科技有限責任公司 チロシンキナーゼ阻害剤としてのインドリノン誘導体
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
CA2919498C (en) 2013-07-31 2023-07-25 Windward Pharma, Inc. Aerosol nintedanib compounds and uses thereof
HUE059606T2 (hu) 2014-08-28 2022-11-28 Eisai R&D Man Co Ltd Nagy tisztaságú kinolinszármazék és eljárás elõállítására
CN104262232B (zh) * 2014-09-09 2016-05-04 苏州明锐医药科技有限公司 尼泰达尼的制备方法
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (zh) * 2015-06-05 2017-03-08 北京康立生医药技术开发有限公司 一锅法制备尼达尼布的合成方法
CN114010787A (zh) 2015-06-06 2022-02-08 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
JP6757959B2 (ja) 2015-06-16 2020-09-23 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ 抗がん剤
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CZ308695B6 (cs) 2015-07-29 2021-03-03 Zentiva, K.S. Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu)
CN106467500A (zh) * 2015-08-14 2017-03-01 廊坊百瑞化工有限公司 一种一锅煮法合成尼达尼布关键中间体的新方法
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
LT3722291T (lt) * 2015-12-24 2023-12-11 Respivert Limited Indolino junginiai ir jų panaudojimas fibrozinių ligų gydymui
CZ2016104A3 (cs) 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
BR112018068213A2 (pt) 2016-03-08 2019-01-29 Respivert Ltd derivados indólicos e seu uso como inibidores de proteína quinase
EP3442534A1 (en) 2016-04-13 2019-02-20 Boehringer Ingelheim International GmbH Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
US20190275032A1 (en) 2016-05-27 2019-09-12 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for determining the treatment onset with nintedanib and pirfenidone
WO2017207643A1 (en) 2016-06-01 2017-12-07 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
CN119656170A (zh) 2016-06-02 2025-03-21 拨康视云生物医药科技(广州)有限公司 使用尼达尼布来治疗具有异常新生血管形成的眼病的组合物和方法
CN114569606B (zh) 2016-07-29 2024-04-19 英克特诺治疗公司 吲哚啉酮化合物的用途
CN106748961A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的杂质化合物、制备方法、应用及其检测方法
CN106748960A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法
EP3551187B1 (en) 2016-12-12 2021-02-17 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
BR112019014127A2 (pt) 2017-02-08 2020-02-11 Eisai R&D Management Co., Ltd. Composição farmacêutica para tratamento de tumores
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
MX2019013014A (es) 2017-05-16 2020-08-06 Eisai R&D Man Co Ltd Tratamiento de carcinoma hepatocelular.
IL273169B2 (en) 2017-10-23 2024-05-01 Boehringer Ingelheim Int New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
CA3082714A1 (en) 2017-11-17 2019-05-23 Fermion Oy Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib
JP7061310B2 (ja) * 2018-04-05 2022-04-28 国立大学法人 大分大学 慢性脂肪性疾患の予防および治療用医薬
CN108358827A (zh) * 2018-05-07 2018-08-03 日照市普达医药科技有限公司 一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法
EP3813793B1 (en) 2018-05-25 2023-09-20 ADS Therapeutics LLC A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
PE20211054A1 (es) * 2018-10-05 2021-06-07 Ichnos Sciences S A Compuestos de indolinona para uso como inhibidores de map4k1
JP2023519600A (ja) 2020-04-01 2023-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維性状態の治療におけるバイオマーカーの使用
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN112574094B (zh) * 2020-12-14 2022-07-01 成都大学 吲哚酮衍生物及其制药用途
EP4282874A4 (en) 2021-01-25 2024-08-28 Nibec Co., Ltd. Peptide for preventing and treating fibrosis
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN115703758B (zh) * 2021-08-12 2024-03-26 中国医学科学院药物研究所 一类用作激酶抑制剂的化合物及其制备方法和用途
EP4572763A1 (en) 2022-08-16 2025-06-25 Boehringer Ingelheim International GmbH Pharmaceutical formulations of nintedanib for intraocular use
TWI857798B (zh) * 2023-09-28 2024-10-01 國立臺灣大學 用於治療及/或預防腫瘤或細胞增生及纖維化疾病之吲哚啉衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558210A (forum.php) * 1956-06-08
AU684950B2 (en) * 1994-05-06 1998-01-08 Alcon Laboratories, Inc. Use of vitamin E tocopheryl derivatives in ophthalmic compositions
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ATE243034T1 (de) * 1996-01-17 2003-07-15 Taiho Pharmaceutical Co Ltd Intimale verdickungsinhibitoren
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19824922A1 (de) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
LU92681I2 (fr) 2015-05-18
LTC1224170I2 (lt) 2023-11-10
HK1052505B (zh) 2009-06-26
CY2015009PI2 (el) 2016-12-14
DK1224170T3 (da) 2009-12-07
CZ20021410A3 (cs) 2002-07-17
JP2007302697A (ja) 2007-11-22
CN100455568C (zh) 2009-01-28
SA01210704B1 (ar) 2006-12-05
HK1052505A1 (zh) 2003-09-19
BRPI0014735B1 (pt) 2012-07-10
MEP45408A (en) 2011-02-10
SK6462002A3 (en) 2002-08-06
FR15C0024I2 (fr) 2016-08-26
HUP0204587A2 (en) 2003-05-28
HUS1600022I1 (hu) 2017-02-28
ES2331459T3 (es) 2010-01-05
IL148756A (en) 2007-10-31
JP2003511441A (ja) 2003-03-25
HUP0204587A3 (en) 2004-07-28
KR20070095996A (ko) 2007-10-01
PT1224170E (pt) 2009-10-01
BG106587A (bg) 2003-01-31
CN1391557A (zh) 2003-01-15
UA75054C2 (uk) 2006-03-15
HRP20020306A2 (en) 2003-10-31
NZ518489A (en) 2005-05-27
KR20020038949A (ko) 2002-05-24
NL300725I2 (nl) 2017-07-13
CY1110067T1 (el) 2015-01-14
BG65983B1 (bg) 2010-08-31
FR15C0024I1 (forum.php) 2015-04-17
BRPI0014735A (pt) 2002-07-16
AR026036A1 (es) 2002-12-26
HRP20020306B1 (en) 2010-09-30
NO322746B1 (no) 2006-12-04
TWI268922B (en) 2006-12-21
CA2387013A1 (en) 2001-04-19
EE05427B1 (et) 2011-06-15
MY127956A (en) 2007-01-31
NO20021719D0 (no) 2002-04-11
YU26602A (sh) 2004-11-25
EP1224170B1 (de) 2009-08-12
RS51013B (sr) 2010-10-31
EP1224170B9 (de) 2017-11-22
EA200200380A1 (ru) 2002-10-31
AU781939B2 (en) 2005-06-23
PE20010671A1 (es) 2001-06-28
CO5261488A1 (es) 2003-03-31
CA2387013C (en) 2009-12-29
NO2015009I2 (forum.php) 2015-03-18
MXPA02002799A (es) 2003-02-27
LU92681I9 (forum.php) 2019-01-03
IL148756A0 (en) 2002-09-12
LTPA2015015I1 (lt) 2015-04-27
SK287312B6 (sk) 2010-06-07
KR100857734B1 (ko) 2008-09-10
SI1224170T1 (sl) 2009-12-31
CZ301073B6 (cs) 2009-10-29
EE200200197A (et) 2003-06-16
AU1023301A (en) 2001-04-23
EG25931A (en) 2012-10-24
PL355433A1 (pl) 2004-04-19
NO2023033I1 (no) 2023-09-05
CY2015009PI1 (el) 2016-12-14
NO20021719L (no) 2002-04-11
NO2015009I1 (no) 2015-03-30
EA006080B1 (ru) 2005-08-25
PL207445B1 (pl) 2010-12-31
EP2157081A1 (de) 2010-02-24
JP4021664B2 (ja) 2007-12-12
WO2001027081A1 (de) 2001-04-19
ATE439342T1 (de) 2009-08-15
DE50015711D1 (de) 2009-09-24
BE2015C018I2 (forum.php) 2019-10-23
DK1224170T5 (en) 2018-01-22
BRPI0014735B8 (pt) 2021-07-06
EP1224170A1 (de) 2002-07-24
KR100835546B1 (ko) 2008-06-09

Similar Documents

Publication Publication Date Title
HU230416B1 (hu) 6-Helyzetben szubsztituált indolinonok, előállításuk és alkalmazásuk gyógyszerként
JP7307744B2 (ja) がん治療のための１－（ピペリジノカルボニルメチル）－２－オキソピペラジン誘導体
RU2167864C2 (ru) Производные индолин-2-она, способ их получения и содержащие их фармацевтические композиции
TWI363628B (en) Certain chemical entities, compositions, and methods
JP2004520324A (ja) カルバゾール誘導体およびニューロペプチドｙ５受容体リガンドとしてのそれらの使用
EP0764152A1 (en) Substituted indolylmethylene-oxindole analogues as tyrosine kinase inhibitors
US9611224B2 (en) Antiproliferative benzo [B] azepin-2-ones
TW200403060A (en) Inhibitors of tyrosine kinases
TW200800899A (en) Novel compounds
TW200911233A (en) Substituted indazole derivatives active as kinase inhibitors
JP2001518895A (ja) ソマトスタチン作働薬
TW200412957A (en) Therapeutic agents
WO2002060392A2 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US10906884B2 (en) Benzodiazepine derivatives as CCK2/gastrin receptor antagonists
KR101475168B1 (ko) 암 치료용 신규 ｎ-하이드록시-벤즈아마이드
US20100331355A1 (en) Substituted Quinolines for the Treatment of Cancer
CA2481855A1 (en) Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
EA028604B1 (ru) Модуляторы рецептора cxcr7
AU2008200385A1 (en) Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
EP3956315B1 (en) Benzo- and pyrido-pyrazoles as protein kinase inhibitors
CZ64499A3 (cs) Substituované 1,2,3,4-tetrahydro-2-dibenzofuranaminy a 2-aminocyklohepta[b]benzofurany
US20230234917A1 (en) Asparagine derivatives and methods of using same
TW200948356A (en) Homocysteine synthetase inhibitors
TW200911757A (en) Crystalline forms of histone deacetylase inhibitors
CA3152923A1 (en) Bet degrader

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: NINTEDANIB, ITS TAUTOMERS AND THEIR SALTS, ESPECIALLY NINTEDANIB AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS, TYPICALLY NINTEDANIB ESYLATE; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141125

Spc suppl protection certif: S1600022

Filing date: 20160513

Expiry date: 20201009

FG4S Grant of supplementary protection certificate

Free format text: PRODUCT NAME: NINTEDANIB, ITS TAUTOMERS AND THEIR SALTS, ESPECIALLY NINTEDANIB AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS, TYPICALLY NINTEDANIB ESYLATE; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141125

Spc suppl protection certif: S1600022

Filing date: 20160513

Expiry date: 20201009

Extension date: 20251009